This company listing is no longer active
TFFP Stock Overview
A clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
TFF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.065 |
| 52 Week High | US$11.00 |
| 52 Week Low | US$0.061 |
| Beta | 1.06 |
| 1 Month Change | -82.72% |
| 3 Month Change | -97.03% |
| 1 Year Change | -99.17% |
| 3 Year Change | -99.97% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?
Apr 10
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?
Sep 27TFF Pharma: The Potential Is Still Very Much Present
Aug 29TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways
Aug 09TFF Pharmaceuticals expands R&D operations with new Austin facility
Jul 14TFF Pharmaceuticals: A Highly Attractive Basket Of Options
May 23Shareholder Returns
| TFFP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -77.6% | 3.2% | -1.1% |
| 1Y | -99.2% | -12.4% | 9.1% |
Return vs Industry: TFFP underperformed the US Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: TFFP underperformed the US Market which returned 27.6% over the past year.
Price Volatility
| TFFP volatility | |
|---|---|
| TFFP Average Weekly Movement | 34.0% |
| Pharmaceuticals Industry Average Movement | 11.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: TFFP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TFFP's weekly volatility has increased from 23% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 19 | Craig Jalbert | tffpharma.com |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
TFF Pharmaceuticals, Inc. Fundamentals Summary
| TFFP fundamental statistics | |
|---|---|
| Market cap | US$288.80k |
| Earnings (TTM) | -US$18.52m |
| Revenue (TTM) | US$1.16m |
Is TFFP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TFFP income statement (TTM) | |
|---|---|
| Revenue | US$1.16m |
| Cost of Revenue | US$10.70m |
| Gross Profit | -US$9.54m |
| Other Expenses | US$8.98m |
| Earnings | -US$18.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.17 |
| Gross Margin | -821.41% |
| Net Profit Margin | -1,595.04% |
| Debt/Equity Ratio | 0% |
How did TFFP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/15 23:06 |
| End of Day Share Price | 2024/12/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TFF Pharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |